Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dutch study questions value of radioactive stents:

This article was originally published in Clinica

Executive Summary

A Dutch team has cast doubt over the effectiveness of radioactive stents. The devices delay rather than prevent the development of in-stent neointimal hyperplasia, which is the usual cause of restenosis, say researchers. They implanted radioactive stents emitting beta-radiation in the coronary arteries of 40 patients. Their findings, published in Circulation (January 2/9), showed a "worrying late progression of in-stent neointimal hyperplasia" between six months and one year after implantation. The event-free rate at one year was 53%, which the team says "is not favourable when compared with conventional stenting".

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT069638

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel